Treating a wide range of cataract patients with a unique ZEISS Optic

For US FDA premarket approval of ZEISS CT LUCIA^® 621P, a US clinical trial^a using the ZEISS CT LUCIA 611P^b as study device was performed in a multicentric setting by 23 US surgeons over 15 sites.

The ZEISS CT LUCIA^® 611P^b exhibited excellent refractive stability in the first post-operative year with minimal and insignificant changes in the manifest refraction spherical equivalent (MRSE).

^{a) Schallhorn SC, Bonilla M, Pantanelli SM. Outcomes of a multicenter U.S. clinical trial of a new monofocal single-piece hydrophobic acrylic IOL. J Cataract Refract Surg. 2022 Oct 1;48(10):1126-1133.}

^{b) The results of the ZEISS CT LUCIA 611P US IDE study are applicable to the ZEISS CT LUCIA 621P IOL. Bench studies have demonstrated equivalent performance between the ZEISS CT LUCIA 621P IOL and the ZEISS CT LUCIA 611P IOL.}